Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Oct 1;11(10):1235-47.
doi: 10.6004/jnccn.2013.0146.

Targeting angiogenesis in advanced non-small cell lung cancer

Philip E Lammers  1 , Leora Horn
Affiliations
Review

Targeting angiogenesis in advanced non-small cell lung cancer

Philip E Lammers et al. J Natl Compr Canc Netw. .

Abstract

Lung cancer is the leading cause of cancer-related mortality in the United States. Over the past 40 years, treatments with standard chemotherapy agents have not resulted in substantial improvements in long-term survival for patients with advanced lung cancer. Therefore, new targets have been sought, and angiogenesis is a promising target for non-small cell lung cancer (NSCLC). Bevacizumab, a monoclonal antibody targeted against the vascular endothelial growth factor, is the only antiangiogenic agent currently recommended by NCCN for the treatment of advanced NSCLC. However, several antibody-based therapies and multitargeted tyrosine kinase inhibitors are currently under investigation for the treatment of patients with NSCLC. This article summarizes the available clinical trial data on the efficacy and safety of these agents in patients with advanced lung cancer.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest

The authors have no potential conflicts of interest to disclose.

Figures

Figure 1.
Figure 1.. Targeting angiogenesis in lung cancer.
Receptors and downstream signaling pathways involved in angiogenesis and sites of action of anti-angiogenic antibody-based therapies and multi-targeted TKIs.
See this image and copyright information in PMC

References

    1. American Cancer Society. Cancer Facts & Figures, 2013. Atlanta, GA: American Cancer Society; 2013.
    1. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology™ Non-Small Cell Lung Cancer. V.3.2012 http://www.nccn.org/professionals/physician_gls/PDF/nscl.pdf.
    1. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92–98. - PubMed
    1. Kris MG, Johnson BE, Kwiatkowski DJ, et al. Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: The NCI’s Lung Cancer Mutation Consortium (LCMC). J Clin Oncol 2011;29 (suppl). Abstract CRA7506.
    1. Lucchi M, Mussi A, Fontanini G, et al. Small cell lung carcinoma (SCLC): the angiogenic phenomenon. Eur J Cardiothorac Surg 2002;21:1105–1110. - PubMed

Publication types

MeSH terms